Q1 Earnings Estimate for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Medpace in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Cherny expects that the company will post earnings per share of $3.03 for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%.

Several other research analysts also recently commented on the company. Leerink Partners assumed coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $376.30.

Medpace Stock Down 2.1 %

Shares of Medpace stock opened at $317.65 on Wednesday. The stock has a market capitalization of $9.68 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a 50-day simple moving average of $336.81 and a 200 day simple moving average of $339.41.

Institutional Investors Weigh In On Medpace

A number of institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd acquired a new position in Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the 4th quarter valued at $31,000. Stone House Investment Management LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $33,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the last quarter. Finally, Lindbrook Capital LLC grew its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.